Cell Therapy News 18.30 September 11, 2017 | |
| |
TOP STORYExperiments in an in vivo repair model showed that collagen-mimetic peptide modification enabled tailoring of transgene expression from 4 to 25 days over a range of concentrations. [Acta Biomater] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Transplanted human intestinal organoids (hIOs) under the kidney capsule were tracked with fluorescence imaging (FLI) and confirmed histologically. After orthotopic transplantation, the localization of the hIOs in the small intestine could be accurately visualized using FLI. [FASEB J] Abstract The authors examined the transplantation of three-dimensional artificial human lymphatic network tissue (AHLT) fabricated by the cell accumulation technique into the subcutaneous tissue and fascia of mice. Two weeks after transplantation, the AHLT showed engraftment of artificial lymphatic vessels immunopositive for human CD31 and human podoplanin. [J Tissue Eng Regen Med] Abstract The effects of type 1 T regulatory cells on T-cell proliferation and the occurrence of graft versus host disease following allogeneic stem-cell transplantation were investigated. [Cell Physiol Biochem] Full Article Armored CAR T Cells Enhance Antitumor Efficacy and Overcome the Tumor Microenvironment In vivo, researchers showed enhanced expansion and CAR T cell antitumor efficacy, culminating in improvement in survival in a syngeneic model of ovarian peritoneal carcinomatosis. [Sci Rep] Full Article Investigators administered prophylactic cytomegalovirus (CMV)-peptide specific T cell infusions, followed by two doses of intradermal CMV peptide-pulsed dendritic cell vaccine to four HSCT patients. [Biol Blood Marrow Transplant] Abstract This Phase I study was conducted to determine the maximum tolerated dose of yttrium-90 (90Y) ibritumomab tiuxetan with high dose melphalan therapy in multiple myeloma patients undergoing autologous stem cell transplantation. [Bone Marrow Transplant] Abstract Scientists investigated the effects of human dental pulp stem cell (DPSC) transplantation in streptozotocin (STZ)-induced neuropathic rats. Six weeks after STZ injection, DPSCs were transplanted through two routes, intravenous or intramuscular, in single or two repeat doses. [Cytotherapy] Abstract Investigators assessed the effectiveness of lentiviral vector mediated Toll-like receptor 2 gene silencing in the survival of transplanted corneal allografts, against immune rejection, in rats. [Mol Immunol] Abstract | |
| |
REVIEWSPromises and Challenges in Hematopoietic Stem Cell Gene Therapy The authors discuss the available vector platforms and preclinical/clinical and basic research that contribute to the current understanding of hematopoietic stem cell-directed gene therapy, as well as some overarching principles that can be concluded from these. [Hum Gene Ther] Abstract Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
SCIENCE NEWSTxCell to Present New Data on CAR-Treg Construct Optimization TxCell SA announced that Li Zhou, PhD, Vice-president Cell Engineering at TxCell, gave an oral presentation and presented a poster with new CAR-Treg-related data. [Press release from Txcell SA discussing research presented at the 2017 CAR-TCR Summit, Boston] Press Release | |
| |
INDUSTRY NEWSLongeveron Initiates Phase IIb Stem Cell Therapy Trial to Treat Aging Frailty Longeveron LLC announced that it treated its first patient in the company’s Phase IIb clinical trial evaluating the safety and efficacy of Longeveron human allogeneic mesenchymal stem cells in patients with aging frailty syndrome. [Longeveron LLC] Press Release Voyager Therapeutics, Inc. announced positive results from its ongoing Phase Ib trial of VY-AADC01 in advanced Parkinson’s disease. The results demonstrated durable, dose-dependent and time-dependent improvements across multiple measures of patients’ motor function after a one-time administration of the gene therapy. [Voyager Therapeutics, Inc.] Press Release New Investment in Cell and Gene Therapy Catapult Manufacturing Center As part of a £197 million investment in the healthcare and life sciences sector, a £12 million award from the UK Government’s Industrial Strategy Challenge Fund will significantly increase the current size and capability of the Cell and Gene Therapy Catapult large-scale Good Manufacturing Practice manufacturing centre. [Cell and Gene Therapy Catapult] Press Release GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology GE Healthcare introduced the first in its VIA Thaw series, the VIA Thaw CB1000 for thawing large volumes of cell therapies cryopreserved in cryo-bags. [GE Healthcare] Press Release FDA Approval Brings First Gene Therapy to the United States The FDA issued a historic action making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia. [U.S. Food and Drug Administration] Press Release Abeona Therapeutics Inc. announced that the FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with recessive dystrophic epidermolysis bullosa. [Abeona Therapeutics Inc.] Press Release Cellectis Reports Clinical Hold of UCART123 Studies Cellectis announced having received notice from the FDA that a clinical hold was placed on both UCART123 ongoing Phase I studies, respectively, in acute myeloid leukemia and in blastic plasmacytoid dendritic cell neoplasm. [Cellectis] Press Release 1st Patient Recruited in Orthocell Ortho-ATI® Shoulder Tendon Study Orthocell Limited announced that it has recruited and treated its first patient in a randomized, controlled clinical trial of Ortho-ATI® versus corticosteroid injection, for the treatment of rotator cuff tendinopathy and tear in the shoulder. [Orthocell Limited (Business Wire Inc.)] Press Release BioCardia®, Inc. announced the issuance of United States Patent No. 9,301,975 relating to a method of producing mesenchymal stem cells from bone marrow cells in a culture medium sourced from the same donor as the cell population being cultured. [BioCardia®, Inc.] Press Release Cryoport announced that Kite Pharma has chosen Cryoport’s industry-leading, advanced technology suite of cryogenic logistics solutions for the life sciences industry to support the potential commercial launch of its lead CAR T-cell therapy, axicabtagene ciloleucel, for the treatment of aggressive non-hodgkin lymphoma. [Cryoport] Press Release Hyundai Hope On Wheels® will present The Beckman Research Institute at City of Hope with a $150,000 Hyundai Young Investigator Grant. The grant funds will support the research of principal investigator Dr. Leo David Wang. One of his first efforts will be to bring CAR-T cell therapy for brain tumors to the pediatric clinic. [Hyundai Hope on Wheels (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSSouth Korean Researchers Lobby Government to Lift Human-Embryo Restrictions More than a decade after a fraud scandal in stem-cell science rocked South Korea, scientists in the field are ramping up pressure on the government to relax the country’s strict regulations on human-embryo research — which many researchers label a ban. The nation’s bioethics committee held a public forum with the Ministry of Health and Welfare in Seoul, inviting eleven researchers and scholars to discuss possible changes to the country’s bioethics policies on research. [Nature News] Editorial Pall Hangs over U.S.-Iran Science Ties Rising tensions between the U.S. and Iranian governments have frozen most scientific contacts between the two nations, experts reported at a forum. [ScienceInsider] Editorial The Minister of Science, Kirsty Duncan, announced $515 million in support for fundamental research through the Natural Sciences and Engineering Research Council of Canada’s (NSERC) 2017 competition for the Discovery Grants program, scholarships and fellowships. This is NSERC’s largest annual investment, and it assists researchers by offering financial support though scholarships, fellowships, research supplements, and equipment grants. [Natural Sciences and Engineering Research Council of Canada] Editorial Senate Panel Seeks Middle Ground on Human Fetal Tissue Research and Abortion A Senate spending panel countered a move by its House of Representatives counterpart to quash federal funding for research that uses human fetal tissue from elective abortions. The move sets up a conflict that will need to be resolved when lawmakers meet later this year to hash out differences between the House and Senate bills, which will provide funding for the National Institutes of Health in the 2018 fiscal year. [ScienceInsider] Editorial
| |
REGULATORYFDADeviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability (FR Doc. No:2017-18737) Notice Review of Existing Center for Drug Evaluation and Research Regulatory and Information Collection Requirements (FR Doc. No:2017-19033) Notice Vaccines and Related Biological Products Advisory Committee; Notice of Meeting (FR Doc. No:2017-19129) Notice
| |
EVENTSNEW Translational Stem Cell Research Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Technologist – Immunotherapy (STEMCELL Technologies Inc.) NEW Postdoctoral Position – NK Cell Therapy (Oslo University Hospital) Technologist – Cell Therapy (Yale New Haven Health) Researcher – Skeletal Tissue Engineering (KU Leuven) Postdoctoral Fellow – Cell Biology, Tumor Immunology and Targeted Therapy (University of Minnesota) Postdoctoral Associate – Enhancer RNA Therapy (Sylvester Comprehensive Cancer Center) Research Group Leaders (Centro de Investigación PrÃncipe Felipe) Research Fellow – Functional Roles of Stem Cell Derived Extracellular Vesicles (Mayo Clinic) Postdoctoral Fellow – Various Projects (University of Oklahoma) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|